Astrocytoma

Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program

...his deadly disease. Cotara has been granted orphan drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration. A Phase I dosimetry trial in GBM patients in the U.S. has completed patient enrollment and a Phase II safet...

European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors

...a multiforme (GBM) concomitantly with radiotherapy and subsequently as monotherapy, and for patients with malignant gliomas, such as GBM or anaplastic astrocytoma (AA), showing recurrence or progression after standard therapy. In the US, TEMODAR is approved for the treatment of adult patients with newly diagnos...

2 gene mutations linked to most common brain cancers -- and longer survival

.... Further analysis of their data showed that glioblastoma and anaplastic astrocytoma patients carrying the mutations survived longer than those who did not, and...was 31 months versus 15 months for those lacking the mutations. Anaplastic astrocytoma patients carrying the mutations were found to have a median survival of 65 ...

Study: Patients 75 years and older with brain tumors may benefit from more aggressive treatment

...ersity Hospitals, looked at the records of 1753 patients who were treated for glioblastoma multiforme (GBM) and of 205 patients treated for anaplastic astrocytoma (AA) between 1991 and 1999. GBMs are the most common malignant brain tumors in adults. AAs are less common, but are treated similarly to GBMs. Both...

Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials

...this deadly disease. Cotara has been granted orphan drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration. About Peregrine Pharmaceuticals Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a po...

Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology

... 0 2 (14%) 2 (14%) Anaplastic Glioma 9 6 2* (33%) 2 (33%) 4 (66%) *1 Patient with Anaplastic astrocytoma and 1 Patient with Anaplastic Oligodendroglioma The median Progression Free Survival (PFS) and Overall Survival (OS) in th...

New Oncogene for Brain Cancer

...ouse model, a team led by Zhang and Professor of Pathology Gregory Fuller, M.D., Ph.D., shows that IGFBP2 plays an active role in the tumorigenesis of astrocytoma and oligodendroglioma. Both cancers are forms of glioma, cancers that develop in the glial cells which normally support and nourish neurons -- that a...

Genetic Fingerprints Identify Brain Tumors' Origins

...nts for the tumors. Brain tumors are the leading cause of cancer-related death in children, and the most common childhood brain tumor is the pilocytic astrocytoma (PA). Approximately 15 percent of all PAs are linked to neurofibromatosis 1 (NF1), a genetic condition that causes childhood brain tumors and is a pri...

Astrocytoma in Medical Technology

2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion

REGENSBURG, Germany, May 10th, 2007 - Antisense Pharma, a German biopharmaceutical company specialized in targeted therapies for malignant tumors, today announced, that data from the Phase IIb-study with AP 12009 in high-grade glioma will be presented at the 43rd Annual Meeting of the American Soc...

Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma

CHICAGO and REGENSBURG - June 21, 2007 - “In anaplastic astrocytoma, AP 12009 as a monotherapy is actually clearly superior to temozolomide,” Prof. Albert Wong, M.D., Stanford University, California, U.S.A. commented on the international Phase IIb study with the TGF-beta 2-inhibitor AP...

CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors

...a multiforme (GBM) concomitantly with radiotherapy and subsequently as monotherapy, and for patients with malignant gliomas, such as GBM or anaplastic astrocytoma (AA), showing recurrence or progression after standard therapy. The CHMP recommendation serves as the basis for a European Commission approval of the...

Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements

...se III study in recurrent or refractory anaplastic astrocytoma patients. Furthermore, 14-month progression rate w...t patients with recurrent or refractory anaplastic astrocytoma will start in Q3 2008. The study drug will be comp... aims to enroll recurrent or refractory anaplastic astrocytoma patients in about 50 centers in 12 countries. In...

Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

...this deadly disease. Cotara has been granted orphan drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration. Cotara is in a Phase I dosimetry trial in GBM patients in the U.S. and a Phase II safety and efficacy trial ...

Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting

...prosan 20 Diagnosed Glioblastoma publication with carmustine Multiforme or Anaplastic only. implant) astrocytoma with Surgery, Gliadel Wafers and Limited Field Radiation Plus Concomitant Temozol...

Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme

... and subsequently as monotherapy treatment. It also is indicated for the treatment of malignant glioma, such as glioblastoma multiforme and anaplastic astrocytoma (AA), showing recurrence or progression after standard therapy. About the EORTC Created in 1962, the European Organisation for Research and Treatmen...

Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India

...rain cancer centers. Cotara has been granted orphan drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration. About Peregrine Pharmaceuticals Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a port...

Astrocytoma in Medical Dictionary

Gliomas

... comprise a class of slow growing, less aggressive tumors of ... anaplastic astrocytoma or grade III astrocytoma (see high-grade gliomas ) ... Gliomas that occur at the brainstem, w...

Astrocytoma in Biological News

Genetic fingerprints identify brain tumors' origins

...nts for the tumors. Brain tumors are the leading cause of cancer-related death in children, and the most common childhood brain tumor is the pilocytic astrocytoma (PA). Approximately 15 percent of all PAs are linked to neurofibromatosis 1 (NF1), a genetic condition that causes childhood brain tumors and is a pri...

Newly identified biomarker detects and regulates spread of brain tumors

...Attractin is elevated in the cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell migration," is published in the November issue of ...udies suggest that measuring attractin levels in patients with grades II-IV astrocytoma should be explored further as a potential biomarker for monitoring the grow...

Astrocytoma in Biological Technology

Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

...his deadly disease. Cotara has been granted orphan drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration. A Phase I dosimetry trial in GBM patients in the U.S. is in the final stages of patient enrollment and a Ph...